The new acquisition is Lilly's ninth since the start of the year, coming just a few weeks after it agreed to buy psychedelic ...

Since taking effect in August 2024, the EU AI Act (Regulation (EU) 2024/1689) has categorised AI tools by risk level. For ...

Cambridge, UK-based Neurocrine Biosciences - partnered with Japan’s Nxera Pharma - has announced it has received IND ...

The FDA issued approvals for Pfizer, Moderna, and Sanofi's 2026 COVID-19 vaccines on Thursday, but is recommending them for the same reduced patient population as last year: all patients 65 and over, ...

But Sohonos has not lived up to its sales potential, despite being the only drug on the market, perhaps owing to relatively ...

Eli Lilly has announced that orforglipron (Foundayo), its oral glucagon-like peptide-1 (GLP-1) receptor agonist, is now ...

Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road after ...

The US FDA announced two De Novo marketing authorisations for novel medical devices this week: A continuous glucose monitor ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell therapy businesses, which will result in the loss of around 300 jobs or ...

Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities. The news comes just over a year after Sanofi's $9 billion acquisition of ...

US President Donald Trump has nominated White House health policy aide Heidi Overton to take up the mantle of commissioner for the Food and Drug Administration (FDA), ending months of speculation over ...